Bliss GVS Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The promoters and promoter group of Bliss GVS Pharma have submitted their yearly disclosure under SEBI's Takeover Regulations for FY ended March 31, 2025. The promoter group, including Mrs. Shruti Vishal Rao, Shibroor Gokuldas Kamath, Punita Sharma, and Ramadas Vasudev Kamath, collectively hold 3,71,87,174 equity shares (approximately 35.29%) of the company. They have declared that no new encumbrance (pledge) has been created on any shares during the year, and the number of encumbered shares as of March 31, 2025 stands at Nil.
This is a routine annual compliance filing and signals that the promoter group has not pledged any of their shares, which is a positive indicator of financial stability and reduces concerns about forced selling. Shareholders can take comfort that promoters retain unencumbered control over their holdings.